INS 115644

Drug Profile

INS 115644

Alternative Names: INS115644; latrunculin B

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wisconsin Alumni Research Foundation
  • Developer Merck & Co
  • Class Antiglaucomas; Heterocyclic bicyclo compounds; Macrolides; Small molecules; Thiazolidines
  • Mechanism of Action Actin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Glaucoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Glaucoma in USA (Ophthalmic, Drops)
  • 16 May 2011 Inspire Pharmaceuticals has been acquired by Merck & Co
  • 09 Nov 2006 Inspire Pharmaceuticals has filed an IND with the FDA in the US for glaucoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top